Retatrutide Pen Clicks: Device Calibration Reference
A research-use reference for the nominal 30mg pen scale, batch proof, and the documentation boundary around dispensing calibration. It does not provide dosing, injection, split-administration, protocol-length, or personal-use instructions.
The 30mg research pen is listed with a nominal 300-click device scale and 0.1mg per click. Those figures describe the product format; they are not a dose recommendation or administration schedule. Current lot/device documentation and an authorised institutional laboratory SOP control dispensing, accessories, handling and disposal.
What Is the Documented Device Scale?
| Specification | Documented value |
|---|---|
| Nominal content | 30mg retatrutide |
| Nominal device scale | 300 clicks |
| Nominal material increment | 0.1mg per click |
| Intended use | In-vitro laboratory research only |
| Operational control | Current lot/device documentation and institutional SOP |
The arithmetic relationship between nominal content and the device scale is a specification check only. This page does not map clinical-trial arms onto the product, calculate product quantities, or instruct a reader to dial, inject, split, titrate, or administer material.
How Should Published Trial Data Be Read?
ClinicalTrials.gov records and peer-reviewed retatrutide publications describe assigned study arms and protocol-controlled procedures carried out by study teams. They are evidence about investigational clinical development, not instructions for a Remy Peptides research product.
For current regulatory status, use the retatrutide approval page. For product identity and batch proof, use the current product and COA library records.
Frequently Asked Questions
Sources
- ClinicalTrials.gov. TRIUMPH-1 retatrutide Phase 3 study record. NCT05929066.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023. doi.org/10.1056/NEJMoa2301972.